ATYPICAL HEMOLYTIC-UREMIC SYNDROME
Clinical trials for ATYPICAL HEMOLYTIC-UREMIC SYNDROME explained in plain language.
Never miss a new study
Get alerted when new ATYPICAL HEMOLYTIC-UREMIC SYNDROME trials appear
Sign up with your email to follow new studies for ATYPICAL HEMOLYTIC-UREMIC SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New oral treatment shows promise for rare blood and kidney disorder
Disease control OngoingThis Phase 3 trial is testing whether an oral medication called iptacopan can safely and effectively treat atypical hemolytic uremic syndrome (aHUS), a rare disease that damages blood vessels and kidneys. The study involves about 50 adult patients who have not previously received…
Matched conditions: ATYPICAL HEMOLYTIC-UREMIC SYNDROME
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
New drug trial offers hope for kids with devastating kidney disorder
Disease control OngoingThis study is testing an investigational drug called crovalimab in children with atypical hemolytic uremic syndrome (aHUS), a rare and serious disease that damages the kidneys. The goal is to see if the drug can safely control the disease by blocking part of the immune system tha…
Matched conditions: ATYPICAL HEMOLYTIC-UREMIC SYNDROME
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New drug trial offers hope for controlling rare blood disorder
Disease control OngoingThis study is testing an investigational drug called crovalimab in adults and adolescents with atypical hemolytic uremic syndrome (aHUS), a rare and serious blood disorder that can damage the kidneys. The main goal is to see if the drug can effectively control the disease and is …
Matched conditions: ATYPICAL HEMOLYTIC-UREMIC SYNDROME
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC